Hypoglycemia associated with the use of gatifloxacin

被引:14
作者
Bhasin, R [1 ]
Arce, FC [1 ]
Pasmantier, R [1 ]
机构
[1] Univ Hosp, Dept Med, Div Endocrinol, Stony Brook, NY USA
关键词
gatifloxacin; hypoglycemia; diabetes; chronic renal failure;
D O I
10.1097/00000441-200511000-00010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We present the histories, clinical findings, and hospital course of three patients who developed hypoglycemia after receiving gatifloxacin. Possible mechanisms for the hypoglycemia are outlined. Case 1: A 89-year-old diabetic male receiving glyburide was given a single dose of gatifloxacin for bronchitis. Thirteen hours later, he was found to be unresponsive with a blood glucose level of 34 mg/dL. The hypoglycemia resolved within 24 hours of stopping gatifloxacin. Case 2: A 80-year-old nondiabetic woman with end-stage renal disease and recent surgery was treated with gatifloxacin, cefepime, and metronidazole for pneumonia. Sixteen hours later, her serum glucose level was 61 mg/dL, and over the next 24 hours was as low as 39 mg/dL. The hypoglycemia resolved within 40 hours of stopping gatifloxacin. Case 3: A 58-year-old diabetic man receiving glyburide was admitted for myocardial infarction and renal failure. Twelve hours after receiving gatifloxacin for pneumonia, his blood glucose level was 60 mg/dL and was as low as 42 mg/dL between 2 and 22.5 hours of a second dose of gatifloxacin. The hypoglycemia resolved within 24 hours of stopping gatifloxacin. Conclusions: Gatifloxacin use may precipitate hypoglycemia in diabetic patients receiving oral hypoglycemic agents and in nondiabetic patients with chronic renal failure. Discontinuation of gatifloxacin results in improvement in glucose homeostasis.
引用
收藏
页码:250 / 253
页数:4
相关论文
共 13 条
[1]  
Baker SE, 2002, ANN PHARMACOTHER, V36, P1722
[2]  
*BRIST MYERS SQUIB, 2001, PACK INS TEQUIN TABL
[3]   Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise [J].
Gajjar, DA ;
LaCreta, FP ;
Kollia, GD ;
Stolz, RR ;
Berger, S ;
Smith, WB ;
Swingle, M ;
Grasela, DM .
PHARMACOTHERAPY, 2000, 20 (06) :76S-86S
[4]   A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men [J].
Gajjar, DA ;
LaCreta, FP ;
Uderman, HD ;
Kollia, GD ;
Duncan, G ;
Birkhofer, MJ ;
Grasela, DM .
PHARMACOTHERAPY, 2000, 20 (06) :49S-58S
[5]  
GRASELA DM, 1999, 39 INT C ANT AG CHEM
[6]   Gatifloxacin-induced hypoglycemia: A case report and review of the literature [J].
Hussein, G ;
Perkins, LT ;
Sternberg, M ;
Bland, C .
CLINICAL RESEARCH AND REGULATORY AFFAIRS, 2002, 19 (04) :333-339
[7]   Increase in insulin release from rat pancreatic islets by quinolone antibiotics [J].
Maeda, N ;
Tamagawa, T ;
Niki, I ;
Miura, H ;
Ozawa, K ;
Watanabe, G ;
Nonogaki, K ;
Uemura, K ;
Iguchi, A .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (02) :372-376
[8]   Drug-induced hypoglycemia [J].
Marks, V ;
Teale, JD .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1999, 28 (03) :555-+
[9]   Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents [J].
Menzies, DJ ;
Dorsainvil, PA ;
Cunha, BA ;
Johnson, DH .
AMERICAN JOURNAL OF MEDICINE, 2002, 113 (03) :232-234
[10]  
Parilo Miguel A., 2002, Journal of Pharmacy Technology, V18, P319